"Tonix Pharmaceuticals (TNXP) recently received FDA approval for a new drug, which could serve as a significant catalyst for growth, while the company has also confirmed its cash stability amidst a successful fibromyalgia campaign. However, the overall sentiment remains cautious, with risks associated with ongoing financial losses and the uncertain outcomes of future drug approvals reflected in a low sentiment score of 0.28."